This is not a story about a company that did something great. It’s about a company that got luckier than most investors realize — and why that luck might be structural.
Alnylam Pharmaceuticals surged as much as 18% in premarket trading on Thursday after Ionis Pharmaceuticals and its partner AstraZeneca disclosed that their Phase 3 CARDIO-TTRansform trial of eplontersen, marketed as Wainua, failed to meet its primary efficacy endpoint in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
The drug missed the composite goal of reducing cardiovascular mortality and recurrent cardiovascular events over 140 weeks compared to placebo. AstraZeneca shares fell nearly 9%. Ionis tumbled over 20%.
What’s interesting is how cleanly the market read the second-order trade. Alnylam’s AMVUTTRA (vutrisiran) already leads the ATTR-CM market. Today’s competitor failure did not just remove near-term pricing pressure. It eliminated what Wall Street had treated as the most credible threat to Alnylam’s franchise dominance.
The numbers make the competitive context clear. In Q1 2026, Alnylam’s ATTR franchise grew 153% year over year to $910 million, with total product revenue crossing $1 billion in a single quarter for the first time in company history. Full-year 2026 guidance calls for combined net product revenue of $4.9 billion to $5.3 billion, representing roughly 71% growth at the midpoint.
Slight tangent, but it matters: this is also a story about the difficulty of challenging an RNAi mechanism in a disease space that has already been reshaped by gene-silencing biology. The CARDIO-TTRansform failure was not random. A majority of enrolled patients were already receiving TTR stabilizer therapy at baseline, and adding eplontersen on top provided no statistically significant additional benefit. That result doesn’t just close the Wainua chapter. It reinforces why Alnylam’s platform-level approach is harder to displace than a single-molecule competitor.
Stifel maintained its Buy rating immediately following the news, noting that the trial result removes a key valuation overhang from the competitive landscape. BridgeBio Pharma, another ATTR-CM player, also rallied on the news. The market was rapidly repricing who controls this space for the next several years.
Here’s where it gets more interesting. Even with today’s surge, Alnylam shares had been down roughly 24% year to date through the end of June. The stock still trades well below its 52-week high of $495.55. The analyst consensus price target sitting around $436 represents meaningful upside from levels even after the morning spike.
The pipeline is not standing still either. Nucresiran, the next-generation RNAi therapeutic targeting ATTR amyloidosis, is in Phase 3 development. Zilebesiran is in late-stage trials for hypertension. An early-stage obesity program just initiated a Phase 1 study. This is a company transitioning from rare disease specialist into what looks increasingly like a broad-based internal medicine platform.
What Investors Are Watching
The remaining competitive threats in ATTR-CM are fewer but real. Pfizer’s tafamidis and BridgeBio’s acoramidis remain commercial alternatives in the stabilizer class. But neither operates via RNAi, and today’s data reinforces that adding a second mechanism on top of established TTR stabilization does not translate into clinical benefit in a meaningful portion of the patient population.
That distinction matters. Alnylam’s mechanism works differently and the clinical data continues to hold up in conditions where competitor approaches have struggled.
The Q2 2026 earnings call, when it comes, will be the next real test. Management will need to show that AMVUTTRA prescription momentum is sustainable and that the international rollout is tracking toward the full-year revenue target. If those numbers hold, today’s competitive windfall starts looking less like a one-day event and more like a revaluation moment the market had been deferring.
For traders watching options activity: implied volatility expanded sharply on the move. The stock’s elevated IV environment following this kind of binary catalyst shift typically creates opportunities on both sides. A defined-risk structure using call spreads or cash-secured puts at levels near the previous base could offer positioning for investors who believe the competitive moat just widened materially. As always, defined risk is the discipline that matters when biotech headlines are moving the tape this fast.
The question worth sitting with is not whether today’s move was justified. It clearly was. The real question is whether the market has now fully priced what it means to be the last credible RNAi platform standing in one of cardiology’s fastest-growing rare disease categories — or whether this is still the beginning of that repricing.
